Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 51

Determine the efficacy of BMP and MEK inhibitors with RT ...

We and others co-discovered the presence of activating mutations in ACVR1 in 25% of human DIPGs in 2014. Subsequently, my laboratory has developed a murine DIPG model incorporating R206H ACVR1 and observed that R206H ACVR1 significantly accelerates brainstem gliomagenesis. In addition, short-term treatment with a bone morphogenetic protein pathway inhibitor (...

Polyamine pathway metabolism as a novel therapeutic option for Diffuse ...

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive of all childhood cancers. Standard treatment with radiotherapy is only palliative and chemotherapy has been found ineffective. Polyamines are organic compounds essential for key functions of living cells. They can be made by human cells but also generated from intestinal microorganisms ...

study of radiotherapy and concurrent bevacizumab temozolamide followed by bevacizumab. ...

Five-year overall survival in children with high-grade glioma (HGG) and diffuse, intrinsic brainstem glioma (DIPG) are  approximately 25% and 10%, respectively 1-3.  Achieving cure for all children with HGG and DIPG  remains a major goal of pediatric neuro-oncology. DIPGs are infiltrative gliomas, and have typically been found to be &...

Investigating the role of DIPG-derived exosomes in tumor growth and ...

Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive and infiltrating brain tumor affecting children for which there is no effective treatment. Sequencing data have revealed  the existence of well defined subgroups of tumors based on age of onset, specific location in the brain, mutations and clinical outcome. Those ...

MRI Guided Focused Ultrasound: Targeted Drug Delivery in Diffuse Intrinsic ...

Hypothesis & Anticipated Results Diffuse Intrinsic Pontine Glioma, (DIPG) is a fatal cancer and the leading cause of death from  brain tumours in young children. Despite numerous existing chemotherapeutic agents and  promising new molecular therapies, one overriding challenge remains: to overcome the blood  brain barrier (BBB) and ...